2023
Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants
Trainer A, Xu W, Chase A, O'Dell R, Tun S, Li J, Ju S, van Dyck C, Mecca A, Fredricks C. Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079435.Peer-Reviewed Original ResearchAmnestic Alzheimer's diseaseLogopenic variant primary progressive aphasiaPosterior cortical atrophyFunctional connectivity mapsHigher tau burdenFunctional connectivityTau burdenAlzheimer's diseaseConnectivity mapsLongitudinal tau-PETSpread of tauVariant primary progressive aphasiaFusiform gyrusFrontal eye fieldPrimary progressive aphasiaBrains of participantsTau PET scansSuperior parietal lobulePatient-specific biomarkersCortical atrophyCommon subtypeTau-PETHealthy controlsParietooccipital cortexPET scans
2022
Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology
Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, McDade E, van Dyck C, Klein G, Pariente J, Bateman R, Morris J, Perrin R, Benzinger T. Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063285.Peer-Reviewed Original ResearchPrimary age-related tauopathyTau-PET bindingTau-PETTemporal gyrusPET bindingBeta-amyloid pathologyAge-related tauopathyRostral middle frontal gyrusSubthreshold levelsElevated tracer uptakeTau PET imagingTau bindingInferior temporal gyrusInferior temporal cortexMiddle frontal gyrusSuperior temporal gyrusEffect of ageAlzheimer pathologyAmyloid pathologySignificant positive associationLateral parietalTemporal cortexTracer uptakeAlzheimer's diseaseSecondary analysisExamining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology
Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, van Dyck C, McDade E, Klein G, Pariente J, Bateman R, Morris J, Ances B, Benzinger T, Perrin R. Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.061090.Peer-Reviewed Original ResearchPrimary age-related tauopathyTau-PET bindingTau-PETTemporal gyrusPET bindingBeta-amyloid pathologyAge-related tauopathyRostral middle frontal gyrusElevated tracer uptakeSub-threshold levelsTau PET imagingTau bindingInferior temporal gyrusInferior temporal cortexMiddle frontal gyrusSuperior temporal gyrusAlzheimer pathologyAmyloid pathologySignificant positive association
2020
Gantenerumab in‐depth outcomes
Salloway S, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Gantenerumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038049.Peer-Reviewed Original ResearchSporadic Alzheimer's diseaseAlzheimer's diseaseCognitive endpointsCDR-SBAmyloid PETBiomarker outcomesMutation carriersSecondary clinical outcomesSecondary efficacy endpointsAutosomal dominant Alzheimer's diseaseClinical trial programClinical Alzheimer's diseaseBeta monoclonal antibodySymptomatic Alzheimer's diseaseAnti-amyloid antibodiesCognitive compositeSymptomatic mutation carriersEfficacy endpointPlacebo groupPrimary outcomeClinical outcomesInitial doseFluid biomarkersTau-PETAmyloid reductionOverview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab
Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041129.Peer-Reviewed Original ResearchDisease prevention trialsPrevention trialsAlzheimer's disease prevention trialsDifferent antigenic targetsSignificant neuronal lossKey secondary outcomesParallel-group trialAD prevention trialsAdaptive platform trialFuture clinical trialsBeta monoclonal antibodyTiming of treatmentSymptomatic ADLast patientSecondary outcomesSymptom onsetNeuronal lossTop-line resultsTreatment trialsTau-PETAntigenic targetsBrain damageClinical trialsPlatform trialsAD hypotheses